Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial. Mortezavi A. Eur Urol 2025 Oct 31:S0302-2838(25)04777-3. doi: 10.1016/j.eururo.2025.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mortezavi A. Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial. Eur Urol 2025 Oct 31:S0302-2838(25)04777-3. doi: 10.1016/j.eururo.2025.
PMID: 41176433